ClinicalTrials.gg
RecruitingNCT06234826IC-MPSUpdated Jan 31, 2024

Skeletal Muscle Wasting in ICU Patients

An observational study in Critical Illness and Muscle Atrophy, sponsored by Frank Vandenabeele. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-01-31.

Primary conditionMuscular AtrophyRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Muscular Atrophy
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Muscular Atrophy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Frank Vandenabeele · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Muscular Atrophy with a site in Belgium — 2 open to participants now, 4 under way, 2 of them phase 3. Muscular Atrophy · Belgium.

Started
2023
with 3 others
Observational
4 of 19
2 open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
Frank Vandenabeele

Among the 19 studies in Muscular Atrophy with a site in Belgium, this one is one of 4 that started in 2023, is one of 4 observational ones, and was the 18th registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

2 of the 19 studies in Muscular Atrophy with a site in Belgium are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Muscular Atrophy with a site in Belgium, or all of them as a file.
02

Study summary

Muscle wasting occurs rapidly in critically ill patients and impacts both short and long term outcomes. Altered protein metabolism drives muscle loss in ICU patients, with muscle protein breakdown exceeding muscle protein synthesis (MPS). Interventions aimed at attenuating muscle loss by stimulating MPS rates are hampered by a lack of knowledge on altered muscle protein turnover rates during critical illness. Only a few studies have specifically assessed muscle protein synthesis by using contemporary intravenous stable isotope infusions, which allows the assessment of MPS over a short (\<9 hours) period of time. Results from such acute studies can be difficult to extend or translate into long-term clinical practice and outcomes. Oral deuterated water (2H2O) dosing provides an alternative method that can be utilized to extend the measurement of muscle protein synthesis over a period of several days or weeks. It could therefore provide a valuable tool to study muscle protein synthesis during ICU admission and the impact of different anabolic interventions. Although multiple studies using the deuterated water methodology have been performed in both healthy volunteers and patients, it has not yet been performed in critically ill patients.

In this prospective study the investigators aim to assess fractional rates of muscle protein synthesis over a period of (maximal) 7 days in critically ill patients admitted to the intensive care unit. Secondly, the investigators aim to assess mechanisms of acute muscle wasting on an microscopic, ultrastructural and molecular level. Furthermore, the investigators aim to investigate to what extent muscle fibre size is recovered 3 months after ICU discharge.

03

Conditions studied

  • Critical Illness
  • Muscle Atrophy

Browse trials for

04

In context

Muscular Atrophy Reclassified

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

This study's planned enrollment of 20 is below the median of 61 across 73 observational studies indexed under Muscular Atrophy.

Browse Muscular Atrophy studies →

Lead sponsor

This is the only study on the registry with Frank Vandenabeele as lead sponsor.

Compared within Muscular Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

In total 20 patients admitted to the ICU will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age >18y
  • admitted to ICU
  • enteral nutrition line in situ
  • arterial line (any location) in situ
  • expected stay ICU >7d

Exclusion criteria

Exclusion Criteria:

  • spinal cord injury
  • chronic use of before hospital admission
  • to enteral infusion (e.g. due to GI-tract perforation)
  • Kidney or liver failure
  • therapeutic anti coagulation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. muscle protein synthesis rate (%/h)

    obtained by using deuterated water, muscle biopsy sampling and blood sampling

    Time frame: 7 days of stay at the intensive care unit

Secondary outcomes

  1. skeletal muscle fiber characteristics 1

    cross sectional area of muscle fibers

    Time frame: 7 days of stay at the intensive care unit

  2. skeletal muscle fiber characteristics 2

    amount and distribution of muscle fibers (distribution will be calculated as: amount of type X / total amount of fibres)

    Time frame: 7 days of stay at the intensive care unit

  3. mRNA expression in skeletal muscle tissue 1

    mRNA expression in skeletal muscle tissue of MAFBx (atrophy marker)

    Time frame: 7 days of stay at the intensive care unit

  4. mRNA expression in skeletal muscle tissue 2

    mRNA expression in skeletal muscle tissue of MurF1 (atrophy marker)

    Time frame: 7 days of stay at the intensive care unit

  5. mRNA expression in skeletal muscle tissue 3

    mRNA expression in skeletal muscle tissue of FOXO (atrophy marker)

    Time frame: 7 days of stay at the intensive care unit

  6. patient characteristic- age

    age in years

    Time frame: 7 days of stay at the intensive care unit

  7. patient characteristic- body weight

    body weight in kg

    Time frame: 7 days of stay at the intensive care unit

  8. patient characteristic- height

    height in m

    Time frame: 7 days of stay at the intensive care unit

  9. patient characteristic- sex

    male or female

    Time frame: 7 days of stay at the intensive care unit

  10. patient characteristics (medical1)

    mechanical ventilation (duration in days)

    Time frame: 7 days of stay at the intensive care unit

  11. patient characteristics (medical2)

    comorbidities (list of comorbidities)

    Time frame: 7 days of stay at the intensive care unit

  12. patient characteristics (medical3)

    reason hospital admission

    Time frame: 7 days of stay at the intensive care unit

  13. patient characteristic- APACHE score II

    APACHE II score = acute physiology score + age points + chronic health points. Minimum score = 0; maximum score = 71.

    Time frame: 7 days of stay at the intensive care unit

  14. patient characteristic- food intake

    food intake (energy in kcal and protein intake in g/kg/d)

    Time frame: 7 days of stay at the intensive care unit

  15. patient characteristic- LOS

    Length of stay ICU and hospital (in days)

    Time frame: Stay at the intensive care unit and Hospital (up to 1 year)

  16. muscle volume

    3d ultrasound assessed at follow up visit

    Time frame: 3 months post-hospital discharge

  17. habitual food

    Assessed using questionnaires at follow up visit (higher score means better intake)

    Time frame: 3 months post-hospital discharge

  18. habitual activity

    Assessed using questionnaires at follow up visit (higher score means better intake)

    Time frame: 3 months post-hospital discharge

  19. muscle hand grip strength

    hand grip strength using the JAMAR dynamometer in kg

    Time frame: 3 months post-hospital discharge

  20. leg muscle strength

    1RM upper leg at follow up visit

    Time frame: 3 months post-hospital discharge

  21. Functional capacity 1

    SPPB at follow up visit (short physical performance battery)

    Time frame: 3 months post-hospital discharge

  22. Functional capacity 2

    6min walking test at follow up visit

    Time frame: 3 months post-hospital discharge

  23. Quality of life questionnaire

    SF-36 at follow up visit (Short Form Health Survey 36 items) range score between 0-100, lower score represents great health related problems

    Time frame: 3 months post-hospital discharge

  24. Quality of life questionnaires

    Euro-QoL-5D-5-level at follow up visit (Euro quality of life 5 Dimension 5 level) Answers can be converted into EQ-5D index, an utility scores anchored at 0 for death and 1 for perfect health

    Time frame: 3 months post-hospital discharge

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Apr 2025, 24 months after the start.

Of 36 non-industry observational studies under Muscular Atrophy, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 38 studies reached it within 35 months; a quarter within 18 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
Jan 31, 2024
StartActual
Apr 17, 2023
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2025
Last update
Jan 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06234826
Lead sponsor
Frank Vandenabeele
Collaborators
Jessa Hospital
Responsible party
Frank Vandenabeele (principal investigator, Hasselt University) — Sponsor-investigator
First posted
Jan 31, 2024
Start date
Apr 17, 2023
Primary completion
Apr 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Jan 31, 2024

Study contacts

Michelle Weijzen, Dr.
Contact
michelle.weijzen@uhasselt.be
003211268706
Frank Vandenabeele, Prof.
Contact
frank.vandenabeele@uhasselt.be
Frank Vandenabeele, Prof.
principal investigator · Hasselt University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion